P&G acquiring Thorne proves health is a commodity for corporations
By Alma Cordero · Reporting from El Paso ·
When you are poor—when your labor barely covers rent—you don't worry about optimizing your gut microbiome or achieving peak cognitive function by taking a handful of expensive pills.
The Billion Dollar Anxiety Machine
When you are poor—when your labor barely covers rent—you don't worry about optimizing your gut microbiome or achieving peak cognitive function by taking a handful of expensive pills. You worry about the next shift, the next paycheck, if the landlord will raise the rate again. But that is where the corporate machine excels: it takes structural anxiety and repackages it as a consumer choice. That’s what P&G is doing now, acquiring Thorne for $3.8 billion.
From Gut Health to Corporate Portfolio Expansion
The details are staggering enough to make you pause. Procter & Gamble, already owning brands like Metamucil and Align Probiotic, announces this massive acquisition of supplements company Thorne. Shailesh Jejurikar calls it a "play to grow the company’s health business," while Paul Gama describes it as strengthening P&G's position in "premium wellness." The sheer scale—$3.8 billion—is designed to drown out any critical thought. Bizjournals.com and CNBC both reported Jejurikar repeating that they are "really happy with the asset itself," a phrase that translates, if you listen closely, to: We have found another way to extract value. The fact that Thorne’s revenue is heavily sourced from shoppers under 40 only confirms the pattern: we are selling solutions for problems created by capitalism.
A Predictable Pattern of Consolidation
This isn't merely a business deal; it is an echo of history. This mechanism—the deepening market specialization and scientific capability through targeted industry consolidation—is identical to the precedent set by "Merck & Co. acquisitions." In both cases, massive institutions do not innovate out of pure altruism; they consolidate control over essential human needs. They become gatekeepers. The goal is always the same: to ensure that when a symptom appears—be it poor gut function or a lack of affordable housing—the solution must flow through their corporate pipes.
The border region, my friends, has seen this before. It was never about security; it was always about who controlled passage and who profited from the checkpoints. The people doing the country's hardest work have the least standing to complain when the system they rely on is sold off in chunks of billions.
This cycle does not break because a new CEO speaks politely into a microphone. It only breaks when we stop accepting that our health, our stability, and our very right to exist are commodities to be acquired by the highest bidder. The true cost of this acquisition isn't $3.8 billion; it is the further erosion of public understanding that wellness is a human right, not just another quarterly revenue target.